ERBB2 and non-small cell lung carcinoma: HER2 genomic examination by Takezawa et al. revealed that it was amplified in around 12% of NSCLC with acquired resistance to EGFR-TKIs versus in only 1% of untreated lung adenocarcinomas, which is mutually exclusive for the EGFR secondary mutation T790M [20].